

# Detlev Boison

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/381785/publications.pdf>

Version: 2024-02-01

192  
papers

10,993  
citations

20817

60  
h-index

34986

98  
g-index

194  
all docs

194  
docs citations

194  
times ranked

9608  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic variations of adenosine kinase as predictable biomarkers of efficacy of vagus nerve stimulation in patients with pharmacoresistant epilepsy. <i>Journal of Neurosurgery</i> , 2022, 136, 726-735.	1.6	10
2	The impact of methodology on the reproducibility and rigor of DNA methylation data. <i>Scientific Reports</i> , 2022, 12, 380.	3.3	3
3	The metabolic basis of epilepsy. <i>Nature Reviews Neurology</i> , 2022, 18, 333-347.	10.1	68
4	Loss of perivascular aquaporin-4 localization impairs glymphatic exchange and promotes amyloid $\beta^2$ plaque formation in mice. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 59.	6.2	57
5	ATP and Adenosine Metabolism in Cancer: Exploitation for Therapeutic Gain. <i>Pharmacological Reviews</i> , 2022, 74, 799-824.	16.0	38
6	Deep brain stimulation of the anterior thalamus attenuates PTZ kindling with concomitant reduction of adenosine kinase expression in rats. <i>Brain Stimulation</i> , 2022, 15, 892-901.	1.6	4
7	Adenosine A <sub>2A</sub> receptor blockade prevents cisplatin-induced impairments in neurogenesis and cognitive function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	14
8	Adenosine kinase is critical for neointima formation after vascular injury by inducing aberrant DNA hypermethylation. <i>Cardiovascular Research</i> , 2021, 117, 561-575.	3.8	23
9	Adenosine kinase: A key regulator of purinergic physiology. <i>Biochemical Pharmacology</i> , 2021, 187, 114321.	4.4	20
10	Suppression of phrenic nerve activity as a potential predictor of imminent sudden unexpected death in epilepsy (SUDEP). <i>Neuropharmacology</i> , 2021, 184, 108405.	4.1	7
11	Ketogenic Diet, Inflammation, and Epilepsy. <i>Agents and Actions Supplements</i> , 2021, , 185-201.	0.2	1
12	Adenosine Kinase Expression Determines DNA Methylation in Cancer Cell Lines. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 680-686.	4.9	10
13	Adenosine integrates light and sleep signalling for the regulation of circadian timing in mice. <i>Nature Communications</i> , 2021, 12, 2113.	12.8	66
14	Developmental Role of Adenosine Kinase in the Cerebellum. <i>ENeuro</i> , 2021, 8, ENEURO.0011-21.2021.	1.9	7
15	Adenosine kinase expression determines DNA methylation in cancer cell lines. <i>FASEB Journal</i> , 2021, 35, .	0.5	0
16	Specialty Grand Challenge for Brain Disease Mechanisms. <i>Frontiers in Molecular Neuroscience</i> , 2021, 14, 689903.	2.9	1
17	Adenosine kinase: An epigenetic modulator in development and disease. <i>Neurochemistry International</i> , 2021, 147, 105054.	3.8	23
18	The Good, the Bad, and the Deadly: Adenosinergic Mechanisms Underlying Sudden Unexpected Death in Epilepsy. <i>Frontiers in Neuroscience</i> , 2021, 15, 708304.	2.8	21

#	ARTICLE	IF	CITATIONS
19	ATP and adenosine—Two players in the control of seizures and epilepsy development. <i>Progress in Neurobiology</i> , 2021, 204, 102105.	5.7	47
20	Adenosine turnover in GtoPdb v.2021.3. <i>IUPHAR/BPS Guide To Pharmacology CITE</i> , 2021, 2021, .	0.2	0
21	Epigenetics and epilepsy prevention: The therapeutic potential of adenosine and metabolic therapies. <i>Neuropharmacology</i> , 2020, 167, 107741.	4.1	50
22	Upregulation of adenosine A2A receptor and downregulation of GLT1 is associated with neuronal cell death in Rasmussen's encephalitis. <i>Brain Pathology</i> , 2020, 30, 246-260.	4.1	15
23	Effects of Preinjury and Postinjury Exposure to Caffeine in a Rat Model of Traumatic Brain Injury. <i>Journal of Caffeine and Adenosine Research</i> , 2020, 10, 12-24.	0.6	6
24	Ketogenic diet, neuroprotection, and antiepileptogenesis. <i>Epilepsy Research</i> , 2020, 167, 106444.	1.6	27
25	Possible Role of Adenosine in COVID-19 Pathogenesis and Therapeutic Opportunities. <i>Frontiers in Pharmacology</i> , 2020, 11, 594487.	3.5	26
26	Are glia targets for neuropathic orofacial pain therapy?. <i>Journal of the American Dental Association</i> , 2020, 152, 774-779.	1.5	4
27	Compartmentalization of adenosine metabolism in cancer cells and its modulation during acute hypoxia. <i>Journal of Cell Science</i> , 2020, 133, .	2.0	23
28	Hyperexcitability and seizures in the THY-Tau22 mouse model of tauopathy. <i>Neurobiology of Aging</i> , 2020, 94, 265-270.	3.1	11
29	Sarcosine Suppresses Epileptogenesis in Rats With Effects on Hippocampal DNA Methylation. <i>Frontiers in Molecular Neuroscience</i> , 2020, 13, 97.	2.9	6
30	Adenosine kinase inhibition promotes proliferation of neural stem cells after traumatic brain injury. <i>Brain Communications</i> , 2020, 2, fcaa017.	3.3	15
31	Role of Adenosine in Epilepsy and Seizures. <i>Journal of Caffeine and Adenosine Research</i> , 2020, 10, 45-60.	0.6	39
32	Epilepsy Benchmarks Area II: Prevent Epilepsy and Its Progression. <i>Epilepsy Currents</i> , 2020, 20, 14S-22S.	0.8	9
33	Adenosine Kinase Expression in the Frontal Cortex in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2020, 46, 690-698.	4.3	11
34	THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes. <i>British Journal of Pharmacology</i> , 2019, 176, S297-S396.	5.4	423
35	Transient use of a systemic adenosine kinase inhibitor attenuates epilepsy development in mice. <i>Epilepsia</i> , 2019, 60, 615-625.	5.1	42
36	Adenosine Kinase Deficiency Increases Susceptibility to a Carcinogen. <i>Journal of Caffeine and Adenosine Research</i> , 2019, 9, 4-11.	0.6	8

#	ARTICLE	IF	CITATIONS
37	The Purinome and the preBötzing Complex – A Mosaic of Unexplored Mechanisms That May Modulate/Shape the Hypoxic Ventilatory Response. <i>Frontiers in Cellular Neuroscience</i> , 2019, 13, 365.	3.7	8
38	Adenosine Metabolism: Emerging Concepts for Cancer Therapy. <i>Cancer Cell</i> , 2019, 36, 582-596.	16.8	201
39	The role of adenosine in epilepsy. <i>Brain Research Bulletin</i> , 2019, 151, 46-54.	3.0	66
40	Epigenetics and Epilepsy in the Developing Brain. , 2019, , 177-202.		0
41	Adenosine turnover (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	1
42	Commonalities in epileptogenic processes from different acute brain insults: Do they translate?. <i>Epilepsia</i> , 2018, 59, 37-66.	5.1	206
43	Epilepsy and astrocyte energy metabolism. <i>Glia</i> , 2018, 66, 1235-1243.	4.9	158
44	Regulation of Extracellular Adenosine. , 2018, , 13-32.		6
45	New insights into the mechanisms of the ketogenic diet. <i>Current Opinion in Neurology</i> , 2017, 30, 187-192.	3.6	184
46	Adenosine receptors regulate susceptibility to noise-induced neural injury in the mouse cochlea and hearing loss. <i>Hearing Research</i> , 2017, 345, 43-51.	2.0	27
47	Regulation of endothelial intracellular adenosine via adenosine kinase epigenetically modulates vascular inflammation. <i>Nature Communications</i> , 2017, 8, 943.	12.8	69
48	Connexin 43-Mediated Astroglial Metabolic Networks Contribute to the Regulation of the Sleep-Wake Cycle. <i>Neuron</i> , 2017, 95, 1365-1380.e5.	8.1	146
49	Intracellular adenosine regulates epigenetic programming in endothelial cells to promote angiogenesis. <i>EMBO Molecular Medicine</i> , 2017, 9, 1263-1278.	6.9	64
50	Engineering Human Mesenchymal Stem Cells to Release Adenosine Using miRNA Technology. <i>Methods in Molecular Biology</i> , 2017, 1622, 225-239.	0.9	9
51	Mouse Oocytes Acquire Mechanisms That Permit Independent Cell Volume Regulation at the End of Oogenesis. <i>Journal of Cellular Physiology</i> , 2017, 232, 2436-2446.	4.1	13
52	Influence of Adenosine on Synaptic Excitability. , 2017, , 45-76.		0
53	Editorial: Metabolic Control of Brain Homeostasis. <i>Frontiers in Molecular Neuroscience</i> , 2017, 10, 184.	2.9	4
54	Inhibition of Adenosine Kinase Attenuates Acute Lung Injury*. <i>Critical Care Medicine</i> , 2016, 44, e181-e189.	0.9	17

#	ARTICLE	IF	CITATIONS
55	The Biochemistry and Epigenetics of Epilepsy: Focus on Adenosine and Glycine. <i>Frontiers in Molecular Neuroscience</i> , 2016, 9, 26.	2.9	51
56	Adenosine Kinase Inhibition Protects against Cranial Radiation-Induced Cognitive Dysfunction. <i>Frontiers in Molecular Neuroscience</i> , 2016, 9, 42.	2.9	23
57	Dynamic Regulation of the Adenosine Kinase Gene during Early Postnatal Brain Development and Maturation. <i>Frontiers in Molecular Neuroscience</i> , 2016, 9, 99.	2.9	30
58	From unwitnessed fatality to witnessed rescue: Pharmacologic intervention in sudden unexpected death in epilepsy. <i>Epilepsia</i> , 2016, 57, 35-45.	5.1	43
59	Adenosine Kinase Deficiency in the Brain Results in Maladaptive Synaptic Plasticity. <i>Journal of Neuroscience</i> , 2016, 36, 12117-12128.	3.6	39
60	Purines: forgotten mediators in traumatic brain injury. <i>Journal of Neurochemistry</i> , 2016, 137, 142-153.	3.9	28
61	South (S)- and North (N)-Methanocarpa-7-Deazaadenosine Analogues as Inhibitors of Human Adenosine Kinase. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 6860-6877.	6.4	41
62	Adenosinergic signaling in epilepsy. <i>Neuropharmacology</i> , 2016, 104, 131-139.	4.1	107
63	microRNA targeting of the P2X7 purinoceptor opposes a contralateral epileptogenic focus in the hippocampus. <i>Scientific Reports</i> , 2015, 5, 17486.	3.3	98
64	Genetic variation in the adenosine regulatory cycle is associated with posttraumatic epilepsy development. <i>Epilepsia</i> , 2015, 56, 1198-1206.	5.1	49
65	Comorbidities in Neurology: Is adenosine the common link?. <i>Neuropharmacology</i> , 2015, 97, 18-34.	4.1	80
66	MicroRNA Technology and Small-Molecule Delivery. , 2015, , 969-987.		0
67	Deletion of Adenosine A2A Receptors From Astrocytes Disrupts Glutamate Homeostasis Leading to Psychomotor and Cognitive Impairment: Relevance to Schizophrenia. <i>Biological Psychiatry</i> , 2015, 78, 763-774.	1.3	135
68	Ketogenic diet prevents epileptogenesis and disease progression in adult mice and rats. <i>Neuropharmacology</i> , 2015, 99, 500-509.	4.1	124
69	Glycine transporter 1 is a target for the treatment of epilepsy. <i>Neuropharmacology</i> , 2015, 99, 554-565.	4.1	36
70	When GABA Fails: Rundown on Chemokines. <i>Epilepsy Currents</i> , 2014, 14, 155-157.	0.8	1
71	Dravet in the Dish: Mechanisms of Hyperexcitability. <i>Epilepsy Currents</i> , 2014, 14, 279-280.	0.8	1
72	Deep Brain Stimulation in the Dish: Focus on Mechanisms. <i>Epilepsy Currents</i> , 2014, 14, 201-202.	0.8	2

#	ARTICLE	IF	CITATIONS
73	Ketogenic diet sensitizes glucose control of hippocampal excitability. <i>Journal of Lipid Research</i> , 2014, 55, 2254-2260.	4.2	45
74	Overexpression of adenosine kinase in cortical astrocytes and focal neocortical epilepsy in mice. <i>Journal of Neurosurgery</i> , 2014, 120, 628-638.	1.6	32
75	From epidemiology to pathophysiology: what about caffeine in Alzheimer's disease?. <i>Biochemical Society Transactions</i> , 2014, 42, 587-592.	3.4	45
76	Regulation of Fear Responses by Striatal and Extrastriatal Adenosine A2A Receptors in Forebrain. <i>Biological Psychiatry</i> , 2014, 75, 855-863.	1.3	87
77	Homeostatic Control of Synaptic Activity by Endogenous Adenosine is Mediated by Adenosine Kinase. <i>Cerebral Cortex</i> , 2014, 24, 67-80.	2.9	54
78	Role of adenosine in status epilepticus: A potential new target?. <i>Epilepsia</i> , 2013, 54, 20-22.	5.1	34
79	Deletion of striatal adenosine A2A receptor spares latent inhibition and prepulse inhibition but impairs active avoidance learning. <i>Behavioural Brain Research</i> , 2013, 242, 54-61.	2.2	17
80	Glial adenosine kinase â€“ A neuropathological marker of the epileptic brain. <i>Neurochemistry International</i> , 2013, 63, 688-695.	3.8	60
81	Dysregulation of brain adenosine is detrimental to the expression of conditioned freezing but not general Pavlovian learning. <i>Pharmacology Biochemistry and Behavior</i> , 2013, 104, 80-89.	2.9	6
82	Adenosine Receptors and Alzheimerâ€™s Disease. , 2013, , 385-407.		2
83	Adenosine Kinase: Exploitation for Therapeutic Gain. <i>Pharmacological Reviews</i> , 2013, 65, 906-943.	16.0	246
84	Adenosine and Seizure Termination: Endogenous Mechanisms. <i>Epilepsy Currents</i> , 2013, 13, 35-37.	0.8	24
85	Glowing Feet Control the Blood of Seizures. <i>Epilepsy Currents</i> , 2013, 13, 122-123.	0.8	0
86	Chopping Out CHOP Chops the Fate of Neurons. <i>Epilepsy Currents</i> , 2013, 13, 219-220.	0.8	1
87	Ketogenic Diet Improves Core Symptoms of Autism in BTBR Mice. <i>PLoS ONE</i> , 2013, 8, e65021.	2.5	136
88	Homeostatic control of brain function â€“ new approaches to understand epileptogenesis. <i>Frontiers in Cellular Neuroscience</i> , 2013, 7, 109.	3.7	40
89	Silk: A Biocompatible and Biodegradable Biopolymer for Therapeutic Adenosine Delivery. , 2013, , 599-620.		1
90	Epigenetic changes induced by adenosine augmentation therapy prevent epileptogenesis. <i>Journal of Clinical Investigation</i> , 2013, 123, 3552-3563.	8.2	206

#	ARTICLE	IF	CITATIONS
91	Adenosine A2A Receptors in Striatal Glutamatergic Terminals and GABAergic Neurons Oppositely Modulate Psychostimulant Action and DARPP-32 Phosphorylation. PLoS ONE, 2013, 8, e80902.	2.5	64
92	Adenosinergic Perspectives on Schizophrenia: Opportunity for an Integrative Synthesis. , 2013, , 459-491.		0
93	Disruption of Adenosine Homeostasis in Epilepsy and Therapeutic Adenosine Augmentation. , 2013, , 561-579.		0
94	Is Intrinsic Hyperexcitability in CA3 the Culprit for Seizures in Rett Syndrome?. Epilepsy Currents, 2012, 12, 13-14.	0.8	2
95	Adenosine hypothesis of schizophrenia â€œ Opportunities for pharmacotherapy. Neuropharmacology, 2012, 62, 1527-1543.	4.1	160
96	Intact working memory in the absence of forebrain neuronal glycine transporter 1. Behavioural Brain Research, 2012, 230, 208-214.	2.2	11
97	A Scaffold as a Platform for New Therapies?. Epilepsy Currents, 2012, 12, 172-173.	0.8	0
98	A Breather for SUDEP. Epilepsy Currents, 2012, 12, 111-112.	0.8	3
99	Adenosine dysfunction in epilepsy. Glia, 2012, 60, 1234-1243.	4.9	169
100	Epilepsy: Crucial role for astrocytes. Glia, 2012, 60, 1191-1191.	4.9	29
101	Overexpression of ADK in human astrocytic tumors and peritumoral tissue is related to tumor-associated epilepsy. Epilepsia, 2012, 53, 58-66.	5.1	71
102	Caffeine prevents acute mortality after TBI in rats without increased morbidity. Experimental Neurology, 2012, 234, 161-168.	4.1	41
103	Local disruption of glial adenosine homeostasis in mice associates with focal electrographic seizures: A first step in epileptogenesis?. Glia, 2012, 60, 83-95.	4.9	62
104	Adenosine Augmentation Therapy. , 2012, , 1150-1160.		15
105	Adenosine augmentation ameliorates psychotic and cognitive endophenotypes of schizophrenia. Journal of Clinical Investigation, 2012, 122, 2567-2577.	8.2	84
106	Methylxanthines, Seizures, and Excitotoxicity. Handbook of Experimental Pharmacology, 2011, , 251-266.	1.8	66
107	Examining the sex- and circadian dependency of a learning phenotype in mice with glycine transporter 1 deletion in two Pavlovian conditioning paradigms. Neurobiology of Learning and Memory, 2011, 96, 218-229.	1.9	7
108	Modulation of sensorimotor gating in prepulse inhibition by conditional brain glycine transporter 1 deletion in mice. European Neuropsychopharmacology, 2011, 21, 401-413.	0.7	9

#	ARTICLE	IF	CITATIONS
109	The Sound of Noninvasive Seizure Control. <i>Epilepsy Currents</i> , 2011, 11, 196-197.	0.8	4
110	After the Storm: From Windswept to Spiny Trees. <i>Epilepsy Currents</i> , 2011, 11, 155-156.	0.8	0
111	Modulators of Nucleoside Metabolism in the Therapy of Brain Diseases. <i>Current Topics in Medicinal Chemistry</i> , 2011, 11, 1068-1086.	2.1	47
112	Adenosine kinase as a target for therapeutic antisense strategies in epilepsy. <i>Epilepsia</i> , 2011, 52, 589-601.	5.1	84
113	Upregulation of adenosine kinase in astrocytes in experimental and human temporal lobe epilepsy. <i>Epilepsia</i> , 2011, 52, 1645-1655.	5.1	123
114	Adenosine kinase determines the degree of brain injury after ischemic stroke in mice. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2011, 31, 1648-1659.	4.3	49
115	Adenosine kinase inhibition in the cochlea delays the onset of age-related hearing loss. <i>Experimental Gerontology</i> , 2011, 46, 905-914.	2.8	32
116	Glycine transporter 1 as a potential therapeutic target for schizophrenia-related symptoms: Evidence from genetically modified mouse models and pharmacological inhibition. <i>Biochemical Pharmacology</i> , 2011, 81, 1065-1077.	4.4	43
117	Incorporation of proteinase inhibitors into silk-based delivery devices for enhanced control of degradation and drug release. <i>Biomaterials</i> , 2011, 32, 909-918.	11.4	53
118	Homeostatic bioenergetic network regulation: a novel concept to avoid pharmacoresistance in epilepsy. <i>Expert Opinion on Drug Discovery</i> , 2011, 6, 713-724.	5.0	33
119	Arousal Effect of Caffeine Depends on Adenosine A2A Receptors in the Shell of the Nucleus Accumbens. <i>Journal of Neuroscience</i> , 2011, 31, 10067-10075.	3.6	267
120	Selective inactivation of adenosine A2A receptors in striatal neurons enhances working memory and reversal learning. <i>Learning and Memory</i> , 2011, 18, 459-474.	1.3	81
121	A ketogenic diet suppresses seizures in mice through adenosine A1 receptors. <i>Journal of Clinical Investigation</i> , 2011, 121, 2679-2683.	8.2	245
122	Impacts of forebrain neuronal glycine transporter 1 disruption in the senescent brain: Evidence for age-dependent phenotypes in Pavlovian learning. <i>Behavioral Neuroscience</i> , 2010, 124, 839-850.	1.2	13
123	Quantitative analysis of adenosine using liquid chromatography/atmospheric pressure chemical ionization-tandem mass spectrometry (LC/APCI-MS/MS). <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 1493-1498.	2.3	27
124	Silk fibroin encapsulated powder reservoirs for sustained release of adenosine. <i>Journal of Controlled Release</i> , 2010, 144, 159-167.	9.9	86
125	Role of adenosine kinase in cochlear development and response to noise. <i>Journal of Neuroscience Research</i> , 2010, 88, 2598-2609.	2.9	9
126	A novel mouse model for sudden unexpected death in epilepsy (SUDEP): Role of impaired adenosine clearance. <i>Epilepsia</i> , 2010, 51, 465-468.	5.1	105



#	ARTICLE	IF	CITATIONS
127	Inhibitory RNA in epilepsy: Research tools and therapeutic perspectives. <i>Epilepsia</i> , 2010, 51, 1659-1668.	5.1	24
128	Adenosine augmentation therapy for epilepsy. <i>Epilepsia</i> , 2010, 51, 97-97.	5.1	2
129	Manipulation of Adenosine Kinase Affects Sleep Regulation in Mice. <i>Journal of Neuroscience</i> , 2010, 30, 13157-13165.	3.6	68
130	Astrocytes derived from fetal neural progenitor cells as a novel source for therapeutic adenosine delivery. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2010, 19, 390-396.	2.0	10
131	Engineering Human Mesenchymal Stem Cells to Release Adenosine Using miRNA Technology. <i>Methods in Molecular Biology</i> , 2010, 650, 225-240.	0.9	7
132	Adenosine Dysfunction and Adenosine Kinase in Epileptogenesis. <i>The Open Neuroscience Journal</i> , 2010, 4, 93-101.	0.8	38
133	Adenosine dysfunction and adenosine kinase in epileptogenesis. <i>The Open Neuroscience Journal</i> , 2010, 4, 93-101.	0.8	25
134	Adenosine kinase is a new therapeutic target to prevent ischemic neuronal death. <i>The Open Drug Discovery Journal</i> , 2010, 2, 108-118.	0.7	10
135	Editorial [Hot Topic: Adenosine-Based Modulation of Brain Activity (Guest Editor: DETLEV BOISON)]. <i>Current Neuropharmacology</i> , 2009, 7, 158-159.	2.9	10
136	Therapeutic epilepsy research: From pharmacological rationale to focal adenosine augmentation. <i>Biochemical Pharmacology</i> , 2009, 78, 1428-1437.	4.4	62
137	Human mesenchymal stem cell grafts engineered to release adenosine reduce chronic seizures in a mouse model of CA3-selective epileptogenesis. <i>Epilepsy Research</i> , 2009, 84, 238-241.	1.6	82
138	Engineered Adenosine-Releasing Cells for Epilepsy Therapy: Human Mesenchymal Stem Cells and Human Embryonic Stem Cells. <i>Neurotherapeutics</i> , 2009, 6, 278-283.	4.4	46
139	Adenosine augmentation therapies (AATs) for epilepsy: Prospect of cell and gene therapies. <i>Epilepsy Research</i> , 2009, 85, 131-141.	1.6	73
140	Antiepileptic effects of silk-polymer based adenosine release in kindled rats. <i>Experimental Neurology</i> , 2009, 219, 126-135.	4.1	99
141	Astrocytic adenosine kinase regulates basal synaptic adenosine levels and seizure activity but not activity-dependent adenosine release in the hippocampus. <i>Neuropharmacology</i> , 2009, 56, 429-437.	4.1	87
142	Sustained-release silk biomaterials for drug delivery and tissue engineering scaffolds. , 2009, , .		0
143	Deletion of glycine transporter 1 (GlyT1) in forebrain neurons facilitates reversal learning: Enhanced cognitive adaptability?. <i>Behavioral Neuroscience</i> , 2009, 123, 1012-1027.	1.2	22
144	Silk polymer-based adenosine release: Therapeutic potential for epilepsy. <i>Biomaterials</i> , 2008, 29, 3609-3616.	11.4	131

#	ARTICLE	IF	CITATIONS
145	Downregulation of Hippocampal Adenosine Kinase after Focal Ischemia as Potential Endogenous Neuroprotective Mechanism. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2008, 28, 17-23.	4.3	80
146	Regulation of cognition and symptoms of psychosis: Focus on GABAA receptors and glycine transporter 1. <i>Pharmacology Biochemistry and Behavior</i> , 2008, 90, 58-64.	2.9	40
147	The adenosine kinase hypothesis of epileptogenesis. <i>Progress in Neurobiology</i> , 2008, 84, 249-262.	5.7	210
148	Adenosine as a neuromodulator in neurological diseases. <i>Current Opinion in Pharmacology</i> , 2008, 8, 2-7.	3.5	203
149	A Critical Role of the Adenosine A <sub>2A</sub> Receptor in Extrastriatal Neurons in Modulating Psychomotor Activity as Revealed by Opposite Phenotypes of Striatum and Forebrain A <sub>2A</sub> Receptor Knock-Outs. <i>Journal of Neuroscience</i> , 2008, 28, 2970-2975.	3.6	152
150	Uncoupling of astrogliosis from epileptogenesis in adenosine kinase (ADK) transgenic mice. <i>Neuron Glia Biology</i> , 2008, 4, 91-99.	1.6	39
151	Astrogliosis and adenosine kinase: a glial basis of epilepsy. <i>Future Neurology</i> , 2008, 3, 221-224.	0.5	9
152	Adenosine kinase is a target for the prediction and prevention of epileptogenesis in mice. <i>Journal of Clinical Investigation</i> , 2008, 118, 571-82.	8.2	206
153	Acetylcholinesterase. , 2007, , 1-8.		0
154	Suppression of kindling epileptogenesis by adenosine releasing stem cell-derived brain implants. <i>Brain</i> , 2007, 130, 1276-1288.	7.6	151
155	Cell and Gene Therapies for Refractory Epilepsy. <i>Current Neuropharmacology</i> , 2007, 5, 115-125.	2.9	41
156	Enhanced recognition memory following glycine transporter 1 deletion in forebrain neurons.. <i>Behavioral Neuroscience</i> , 2007, 121, 815-825.	1.2	43
157	Lentiviral RNAi-induced downregulation of adenosine kinase in human mesenchymal stem cell grafts: A novel perspective for seizure control. <i>Experimental Neurology</i> , 2007, 208, 26-37.	4.1	87
158	Adenosine-Based Cell Therapy Approaches for Pharmacoresistant Epilepsies. <i>Neurodegenerative Diseases</i> , 2007, 4, 28-33.	1.4	56
159	Pseudocholinesterase. , 2007, , 1-7.		0
160	Transaminases. , 2007, , 1-2.		0
161	4-Aminobutyrate Transaminase. , 2007, , 1-6.		0
162	GlyT-2, Glycine Transporter 2. , 2007, , 1-6.		0

#	ARTICLE	IF	CITATIONS
163	Transgenic Overexpression of Adenosine Kinase Aggravates Cell Death in Ischemia. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2007, 27, 1-5.	4.3	101
164	Neuroprotection in Ischemic Mouse Brain Induced by Stem Cell-Derived Brain Implants. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2007, 27, 919-927.	4.3	43
165	Transgenic overexpression of adenosine kinase in brain leads to multiple learning impairments and altered sensitivity to psychomimetic drugs. <i>European Journal of Neuroscience</i> , 2007, 26, 3237-3252.	2.6	65
166	Adenosine dysfunction in astrogliosis: cause for seizure generation?. <i>Neuron Glia Biology</i> , 2007, 3, 353-366.	1.6	108
167	Drug Induced Neutropenia. , 2007, , 1-3.		1
168	Adenosine as a Modulator of Brain Activity. <i>Drug News and Perspectives</i> , 2007, 20, 607.	1.5	67
169	Adenosine Kinase Expression Modulates Expression of Myelin Proteolipid Protein. <i>The Open Neuroscience Journal</i> , 2007, 1, 15-19.	0.8	3
170	Adenosine Kinase. , 2007, , 1-8.		0
171	GlyT-1, Glycine Transporter 1. , 2007, , 1-6.		1
172	Adenosine A1 receptors are crucial in keeping an epileptic focus localized. <i>Experimental Neurology</i> , 2006, 200, 184-190.	4.1	151
173	Adenosine kinase, epilepsy and stroke: mechanisms and therapies. <i>Trends in Pharmacological Sciences</i> , 2006, 27, 652-658.	8.7	223
174	The support of adenosine release from adenosine kinase deficient ES cells by silk substrates. <i>Biomaterials</i> , 2006, 27, 4599-4607.	11.4	33
175	Disruption of Glycine Transporter 1 Restricted to Forebrain Neurons Is Associated with a Pro-cognitive and Anti-psychotic Phenotypic Profile. <i>Journal of Neuroscience</i> , 2006, 26, 3169-3181.	3.6	144
176	Suppression of Kindled Seizures by Paracrine Adenosine Release from Stem Cell-Derived Brain Implants. <i>Epilepsia</i> , 2005, 46, 1162-1169.	5.1	82
177	Astrogliosis in epilepsy leads to overexpression of adenosine kinase, resulting in seizure aggravation. <i>Brain</i> , 2005, 128, 2383-2395.	7.6	174
178	Adenosine and Epilepsy: From Therapeutic Rationale to New Therapeutic Strategies. <i>Neuroscientist</i> , 2005, 11, 25-36.	3.5	198
179	Seizure suppression and lack of adenosine A1 receptor desensitization after focal long-term delivery of adenosine by encapsulated myoblasts. <i>Experimental Neurology</i> , 2005, 193, 53-64.	4.1	86
180	entla, a Novel Epileptic and Ataxic Cacna2d2 Mutant of the Mouse. <i>Journal of Biological Chemistry</i> , 2004, 279, 7322-7330.	3.4	79

#	ARTICLE	IF	CITATIONS
181	Overexpression of Adenosine Kinase in Epileptic Hippocampus Contributes to Epileptogenesis. <i>Journal of Neuroscience</i> , 2004, 24, 692-701.	3.6	199
182	Engineering embryonic stem cell derived glia for adenosine delivery. <i>Neuroscience Letters</i> , 2004, 370, 160-165.	2.1	65
183	Enhancement of the NMDA receptor function by reduction of glycine transporter-1 expression. <i>Neuroscience Letters</i> , 2004, 373, 79-84.	2.1	79
184	Amino acid composition of brain cysts: levels of excitatory amino acids in cyst fluid fail to predict seizures. <i>Epilepsy Research</i> , 2003, 55, 191-199.	1.6	7
185	Seizure Suppression by Adenosine A <sub>1</sub> Receptor Activation in a Mouse Model of Pharmacoresistant Epilepsy. <i>Epilepsia</i> , 2003, 44, 877-885.	5.1	187
186	Neonatal hepatic steatosis by disruption of the adenosine kinase gene. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 6985-6990.	7.1	190
187	Seizure suppression by adenosine A <sub>2A</sub> receptor activation in a rat model of audiogenic brainstem epilepsy. <i>Neuroscience Letters</i> , 2002, 329, 289-292.	2.1	55
188	Seizure Suppression by Adenosine Releasing Cells Is Independent of Seizure Frequency. <i>Epilepsia</i> , 2002, 43, 788-796.	5.1	59
189	The use of real-time PCR with fluorogenic probes for the rapid selection of mutant neuroectodermal grafts. <i>Journal of Neuroscience Methods</i> , 2002, 120, 85-94.	2.5	3
190	Seizure Suppression in Kindled Rats by Intraventricular Grafting of an Adenosine Releasing Synthetic Polymer. <i>Experimental Neurology</i> , 1999, 160, 164-174.	4.1	71
191	Functional analysis in vivo of the double mutant mouse deficient in both proteolipid protein (PLP) and myelin basic protein (MBP) in the central nervous system. <i>Cell and Tissue Research</i> , 1997, 289, 195-206.	2.9	20
192	Decompaction of CNS myelin leads to a reduction of the conduction velocity of action potentials in optic nerve. <i>Neuroscience Letters</i> , 1995, 195, 93-96.	2.1	54